/
Edwards Lifesciences Corporation is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence, and meaningful partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most.
20.84% operating margin is above average. ROIC at 9.63%. Note that capital returns lag the margin, the business may be capital-intensive despite high margins.
Revenue grew 11.5%, still solid. Margins contracted 4.5pp, which offsets some of the top-line progress.
ROIC dropped from 13.60% to 9.63%, capital efficiency is deteriorating. Operating margin contracted 4.5pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
$6.30B
▲ +11.5% YoY
Net Income (TTM)
$1.10B
▼ -74.3% YoY
Op. Margin
21.37%
▼ -4.5pp YoY
ROIC
10.15%
▼ -4.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$1.09B
▲ +360.5% YoY
Op. Cash Flow (TTM)
$1.36B
▲ +194.2% YoY
Net Debt
-$2.97B
Net Cash Position
Cash & Equiv.
$3.67B
5Y CAGR: +6.7%
5Y CAGR: +15.6%
Continue Research